- Home
- EXAS
as of 12-10-2025 3:45pm EST
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | MADISON |
| Market Cap: | 11.0B | IPO Year: | N/A |
| Target Price: | $77.94 | AVG Volume (30 days): | 10.6M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $38.81 - $101.95 | Next Earning Date: | 11-03-2025 |
| Revenue: | $3,082,033,000 | Revenue Growth: | 14.47% |
| Revenue Growth (this year): | 19.4% | Revenue Growth (next year): | 13.51% |
AI-Powered EXAS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Exact Sciences Corporation (EXAS)
EVP, GM, Precision Oncology
Avg Cost/Share
$70.08
Shares
2,858
Total Value
$200,288.64
Owned After
22,368
SEC Form 4
SVP, General Counsel & Sec
Avg Cost/Share
$70.08
Shares
1,500
Total Value
$105,120.00
Owned After
12,585
SEC Form 4
Director
Avg Cost/Share
$65.00
Shares
12,000
Total Value
$780,000.00
Owned After
60,759
SEC Form 4
SVP, General Counsel & Sec
Avg Cost/Share
$60.00
Shares
1,500
Total Value
$90,000.00
Owned After
12,585
SEC Form 4
Director
Avg Cost/Share
$60.00
Shares
2,000
Total Value
$120,000.00
Owned After
57,962
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Baranick Brian | EXAS | EVP, GM, Precision Oncology | Nov 4, 2025 | Sell | $70.08 | 2,858 | $200,288.64 | 22,368 | |
| Herriott James | EXAS | SVP, General Counsel & Sec | Nov 4, 2025 | Sell | $70.08 | 1,500 | $105,120.00 | 12,585 | |
| Zanotti Katherine S | EXAS | Director | Oct 24, 2025 | Sell | $65.00 | 12,000 | $780,000.00 | 60,759 | |
| Herriott James | EXAS | SVP, General Counsel & Sec | Oct 9, 2025 | Sell | $60.00 | 1,500 | $90,000.00 | 12,585 | |
| Doyle James Edward | EXAS | Director | Oct 9, 2025 | Sell | $60.00 | 2,000 | $120,000.00 | 57,962 |
Compare EXAS vs Leading Stocks
See how EXAS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EXAS Exact Sciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.